In consultation: Guidance and quality standards
Showing 1 to 10 of 21
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487] | Draft guidance | Technology appraisal guidance | |
| Bepirovirsen for treating chronic hepatitis B ID6608 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA ID6540 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Draft guidance | Technology appraisal guidance | |
| Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753] | Draft guidance | Technology appraisal guidance | |
| Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Obinutuzumab for treating serologically active extra-renal lupus [ID6670] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Advanced breast cancer: diagnosis and management (Partial update) | Draft guidance consultation | NICE guideline | |
| Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160] | Review proposal consultation | Technology appraisal guidance | |
| Heart failure - sacubitril valsartan [ID822] | Review proposal consultation | Technology appraisal guidance |